[article]
| Titre : |
Long-term follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum white matter microstructure and neurocognitive outcomes |
| Type de document : |
texte imprimé |
| Auteurs : |
Blake A. GIMBEL, Auteur ; Mary E. ANTHONY, Auteur ; Abigail M. ERNST, Auteur ; Donovan J. ROEDIGER, Auteur ; Erik DE WATER, Auteur ; Judith K. ECKERLE, Auteur ; Christopher J. BOYS, Auteur ; Joshua P. RADKE, Auteur ; Bryon A. MUELLER, Auteur ; Anita J. FUGLESTAD, Auteur ; Steven H. ZEISEL, Auteur ; Michael K. GEORGIEFF, Auteur ; Jeffrey R. WOZNIAK, Auteur |
| Langues : |
Anglais (eng) |
| Mots-clés : |
Child Pregnancy Female Humans Child, Preschool Fetal Alcohol Spectrum Disorders/drug therapy Choline/therapeutic use Corpus Callosum/diagnostic imaging Follow-Up Studies White Matter/diagnostic imaging Choline Cognition Diffusion MRI Fetal alcohol spectrum disorders Longitudinal studies Neurite orientation dispersion and density imaging |
| Index. décimale : |
PER Périodiques |
| Résumé : |
BACKGROUND: Fetal alcohol spectrum disorder (FASD) is a lifelong condition. Early interventions targeting core neurocognitive deficits have the potential to confer long-term neurodevelopmental benefits. Time-targeted choline supplementation is one such intervention that has been shown to provide neurodevelopmental benefits that emerge with age during childhood. We present a long-term follow-up study evaluating the neurodevelopmental effects of early choline supplementation in children with FASD approximately 7 years on average after an initial efficacy trial. METHODS: The initial study was a randomized, double-blind, placebo-controlled trial of choline vs. placebo in 2.5 to 5 year olds with FASD. Participants in this long-term follow-up study include 18 children (9 placebo; 9 choline) seen 7 years on average following initial trial completion. The mean age at follow-up was 11.0 years old. Diagnoses were 28% fetal alcohol syndrome (FAS), 28% partial FAS, and 44% alcohol-related neurodevelopmental disorder. The follow-up included measures of executive functioning and an MRI scan. RESULTS: Children who received choline had better performance on several tasks of lower-order executive function (e.g., processing speed) and showed higher white matter microstructure organization (i.e., greater axon coherence) in the splenium of the corpus callosum compared to the placebo group. CONCLUSIONS: These preliminary findings, although exploratory at this stage, highlight potential long-term benefits of choline as a neurodevelopmental intervention for FASD and suggest that choline may affect white matter development, representing a potential target of choline in this population. TRIAL REGISTRATION: Prior to enrollment, this trial was registered with clinicaltrials.gov ( NCT01149538 ) on June 23, 2010. |
| En ligne : |
https://dx.doi.org/10.1186/s11689-022-09470-w |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575 |
in Journal of Neurodevelopmental Disorders > 14 (2022)
[article] Long-term follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum white matter microstructure and neurocognitive outcomes [texte imprimé] / Blake A. GIMBEL, Auteur ; Mary E. ANTHONY, Auteur ; Abigail M. ERNST, Auteur ; Donovan J. ROEDIGER, Auteur ; Erik DE WATER, Auteur ; Judith K. ECKERLE, Auteur ; Christopher J. BOYS, Auteur ; Joshua P. RADKE, Auteur ; Bryon A. MUELLER, Auteur ; Anita J. FUGLESTAD, Auteur ; Steven H. ZEISEL, Auteur ; Michael K. GEORGIEFF, Auteur ; Jeffrey R. WOZNIAK, Auteur. Langues : Anglais ( eng) in Journal of Neurodevelopmental Disorders > 14 (2022)
| Mots-clés : |
Child Pregnancy Female Humans Child, Preschool Fetal Alcohol Spectrum Disorders/drug therapy Choline/therapeutic use Corpus Callosum/diagnostic imaging Follow-Up Studies White Matter/diagnostic imaging Choline Cognition Diffusion MRI Fetal alcohol spectrum disorders Longitudinal studies Neurite orientation dispersion and density imaging |
| Index. décimale : |
PER Périodiques |
| Résumé : |
BACKGROUND: Fetal alcohol spectrum disorder (FASD) is a lifelong condition. Early interventions targeting core neurocognitive deficits have the potential to confer long-term neurodevelopmental benefits. Time-targeted choline supplementation is one such intervention that has been shown to provide neurodevelopmental benefits that emerge with age during childhood. We present a long-term follow-up study evaluating the neurodevelopmental effects of early choline supplementation in children with FASD approximately 7 years on average after an initial efficacy trial. METHODS: The initial study was a randomized, double-blind, placebo-controlled trial of choline vs. placebo in 2.5 to 5 year olds with FASD. Participants in this long-term follow-up study include 18 children (9 placebo; 9 choline) seen 7 years on average following initial trial completion. The mean age at follow-up was 11.0 years old. Diagnoses were 28% fetal alcohol syndrome (FAS), 28% partial FAS, and 44% alcohol-related neurodevelopmental disorder. The follow-up included measures of executive functioning and an MRI scan. RESULTS: Children who received choline had better performance on several tasks of lower-order executive function (e.g., processing speed) and showed higher white matter microstructure organization (i.e., greater axon coherence) in the splenium of the corpus callosum compared to the placebo group. CONCLUSIONS: These preliminary findings, although exploratory at this stage, highlight potential long-term benefits of choline as a neurodevelopmental intervention for FASD and suggest that choline may affect white matter development, representing a potential target of choline in this population. TRIAL REGISTRATION: Prior to enrollment, this trial was registered with clinicaltrials.gov ( NCT01149538 ) on June 23, 2010. |
| En ligne : |
https://dx.doi.org/10.1186/s11689-022-09470-w |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575 |
|  |
Long-term follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum white matter microstructure and neurocognitive outcomes in Journal of Neurodevelopmental Disorders, 14 (2022)
